Tumors are complex, dynamic systems where surface target accessibility, signaling pathway activation, immune function, and resistance mechanisms all interact to determine therapeutic outcome. Yet oncology programs are making high-stakes decisions, such as which targets to pursue, without the ability to directly measure these mechanisms – relying primarily on genomic and transcriptomic measurements as indirect proxy measures.
Sapient’s Tumor Protein Mapping Platform was built to change that. Our suite of mass spectrometry-based discovery proteomics workflows are designed to quantify functional tumor biology across four critical dimensions: the druggable cell surface proteome, phosphorylation-driven signaling pathways, the tumor immune microenvironment, and therapeutic resistance mechanisms – directly in human tumor tissue.
Enriching for N-linked glycoproteins, this workflow enables comprehensive characterization of surface target accessibility, target density, turnover and internalization.
By directly measuring thousands of phosphorylation events in human tumors, this workflow enables precise characterization of pathway activation and therapeutic response.
Through quantitative profiling of immune cell states and pathways, this workflow delivers mechanistic insight into immune activation, suppression, and response to immunotherapy.
By directly quantifying resistance-associated protein networks in tumors, this workflow helps identify escape mechanisms and rational combination strategies.
Historically, oncology R&D has had to rely upon inferred and fragmented measures to guide decision-making: for example, advancing a target based on protein expression rather than its true accessibility, or from mutation-based inference of pathway activation.
Sapient’s Tumor Protein Mapping Platform addresses this challenge with mass spectrometry for precise, quantitative measurement of tumor biology – at the protein level – across functional dimensions within a unified biological framework. Critical questions can now be probed for:
SurfaceSeek reframes target discovery and validation from qualitative expression analysis to quantitative characterization, aligning target selection with the mechanistic requirements of modern cancer therapeutics. It delivers actionable insights to answer:
SignalingSeek shifts development from mutation-based inference to functional pathway measurement. Insights derived from this direct observation of dynamic human tumor biology can help answer:
ImmuneSeek shifts analysis from inference of tumor immune function to direct measurement of functional pathway activity. This workflow delivers quantitative insight into immune biology that determines therapeutic response, addressing questions such as:
ResistanceSeek shifts development from genomic inference to functional protein measurement across the pathways that define resistance in human tumors – enabling mechanism-driven decision-making. Now resistance can be viewed as a measurable and actionable variable where teams can answer:
Our Tumor Protein Mapping workflows are available as standalone services or can be delivered in combination to provide integrated, multi-dimensional tumor characterization. Connect with our scientists to discuss your study.
